| __timestamp | Amphastar Pharmaceuticals, Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 6620800000 |
| Thursday, January 1, 2015 | 46974000 | 6533000000 |
| Friday, January 1, 2016 | 47298000 | 6452000000 |
| Sunday, January 1, 2017 | 50918000 | 6588100000 |
| Monday, January 1, 2018 | 58044000 | 5975100000 |
| Tuesday, January 1, 2019 | 63109000 | 6213800000 |
| Wednesday, January 1, 2020 | 65157000 | 6121200000 |
| Friday, January 1, 2021 | 68920000 | 6431600000 |
| Saturday, January 1, 2022 | 66592000 | 6440400000 |
| Sunday, January 1, 2023 | 80393000 | 6941200000 |
Igniting the spark of knowledge
In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry giants is crucial. Eli Lilly and Company, a stalwart in the sector, has consistently maintained high Selling, General, and Administrative (SG&A) expenses, averaging around $6.4 billion annually from 2014 to 2023. This reflects their expansive global operations and robust marketing strategies. In contrast, Amphastar Pharmaceuticals, Inc., a smaller player, has seen its SG&A expenses grow by approximately 99% over the same period, from $40 million in 2014 to $80 million in 2023. This growth underscores Amphastar's strategic investments in scaling operations and expanding market reach. The data reveals a fascinating narrative of growth and strategy, highlighting the diverse approaches within the pharmaceutical industry.
Eli Lilly and Company and Vertex Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Biogen Inc.
Eli Lilly and Company and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and United Therapeutics Corporation
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Apellis Pharmaceuticals, Inc.
Revenue Showdown: Eli Lilly and Company vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Eli Lilly and Company and Evotec SE
Johnson & Johnson and Amphastar Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc.
Xenon Pharmaceuticals Inc. and Amphastar Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Soleno Therapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends